Ovarian cancer drug disappoints
* From correspondents in Geneva
* From: AP
* May 28, 2010 5:15AM
SWISS drug maker Novartis says it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.
The drug, patupilone, failed to show improvements over existing drugs in 829 patients with advanced ovarian cancer.
"Novartis does not plan to proceed with regulatory filings based on these data," the Basel-based company said today.
Patupilone also is being tested for treatment of certain types of colorectal, lung and prostate cancer.
Shares in Novartis closed 1.6 per cent higher at 51.85 Swiss francs in line with a general lift on the Zurich exchange.
ovarian cancer drug fails , page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $670.1K | 1.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 44785 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 22453 | 2 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |